Alps Advisors Inc. Sells 5,286 Shares of Agios Pharmaceuticals Inc (NASDAQ:AGIO)

Alps Advisors Inc. cut its position in shares of Agios Pharmaceuticals Inc (NASDAQ:AGIO) by 4.3% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 117,158 shares of the biopharmaceutical company’s stock after selling 5,286 shares during the quarter. Alps Advisors Inc. owned 0.20% of Agios Pharmaceuticals worth $3,796,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. NumerixS Investment Technologies Inc bought a new position in Agios Pharmaceuticals in the second quarter valued at approximately $35,000. US Bancorp DE grew its stake in Agios Pharmaceuticals by 82.6% in the second quarter. US Bancorp DE now owns 1,010 shares of the biopharmaceutical company’s stock valued at $50,000 after purchasing an additional 457 shares in the last quarter. Steward Partners Investment Advisory LLC grew its stake in Agios Pharmaceuticals by 430.6% in the third quarter. Steward Partners Investment Advisory LLC now owns 1,109 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 900 shares in the last quarter. First Mercantile Trust Co. bought a new position in Agios Pharmaceuticals in the third quarter valued at approximately $44,000. Finally, ETF Managers Group LLC grew its stake in Agios Pharmaceuticals by 63.0% in the second quarter. ETF Managers Group LLC now owns 2,851 shares of the biopharmaceutical company’s stock valued at $142,000 after purchasing an additional 1,102 shares in the last quarter.

AGIO has been the subject of a number of analyst reports. Cowen restated a “buy” rating on shares of Agios Pharmaceuticals in a research note on Monday, September 30th. Needham & Company LLC reaffirmed a “buy” rating and issued a $71.00 price objective on shares of Agios Pharmaceuticals in a research report on Thursday, October 31st. Zacks Investment Research cut Agios Pharmaceuticals from a “hold” rating to a “sell” rating and set a $40.00 price objective for the company. in a research report on Monday, September 16th. Guggenheim raised Agios Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $55.00 price objective for the company in a research report on Monday, September 23rd. Finally, Royal Bank of Canada set a $79.00 price target on Agios Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, November 1st. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and nine have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $62.11.

NASDAQ:AGIO opened at $33.56 on Friday. The stock has a market cap of $2.03 billion, a P/E ratio of -5.57 and a beta of 2.22. The stock has a 50 day simple moving average of $33.54 and a 200 day simple moving average of $42.96. The company has a current ratio of 5.30, a quick ratio of 5.24 and a debt-to-equity ratio of 0.24. Agios Pharmaceuticals Inc has a 1-year low of $28.36 and a 1-year high of $71.32.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($1.81) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.85) by $0.04. The firm had revenue of $26.02 million during the quarter, compared to analysts’ expectations of $33.13 million. Agios Pharmaceuticals had a negative return on equity of 70.07% and a negative net margin of 356.42%. The company’s quarterly revenue was up 71.2% compared to the same quarter last year. During the same period in the previous year, the firm earned ($1.63) EPS. As a group, sell-side analysts forecast that Agios Pharmaceuticals Inc will post -7.18 EPS for the current year.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next.

Recommended Story: How to start trading in the forex market?

Want to see what other hedge funds are holding AGIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agios Pharmaceuticals Inc (NASDAQ:AGIO).

Institutional Ownership by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply